———New Amendment]: December 2023.
Docking Personnel": [Zhou Wen].
Global New Injectables Industry Investment Status and Research Risk Analysis Report 2024 2031
Chapter 1: Overview of the development of China's novel injectable industry.
1.1 Overview of the new injectables industry.
1.1.1 Concept and definition of new injectables.
1.1.2 Main product categories of new injections.
1) The current situation of the economic development of the industry.
2) The trend of economic development in the industry.
3) Analysis of the impact of the economic environment on the industry.
1.2.3. Analysis of the social environment of the industry.
1) Current status of adverse reactions of new injections.
2) Water quality for injection.
3) Analysis of the impact of the social environment on the industry.
1.2.4. Analysis of industry demand environment.
1) Population size and structure.
2) Residents' health care expenditures.
3) Analysis of the impact of the demand environment on the industry.
1.2.5. Analysis of the technical environment of the industry.
1) The current state of industry technology.
2) Technological development trends.
3) Analysis of the impact of the technological environment on the industry.
1.3 Analysis of development opportunities and threats in the new injection industry.
Chapter 2: Analysis of the development status of new injectable industries at home and abroad.
2.1 Analysis of the development status of the global new injection industry.
2.1.1 Overview of the development of the global new injection industry.
2.1.2 Global new injectables market size analysis.
2.1.3 Analysis of the global competitive landscape of new injectables.
2.1.4 Structural analysis of global new injectable products.
2.3.2 Analysis of the demand of China's new injection industry.
2.3.3 Analysis of the profitability of China's new injection industry.
2.3.4 Analysis of the trend of China's new injection industry.
2.4 Market competition analysis of China's new injection industry.
2.4.1 Analysis of the competitive landscape of China's new injection industry.
2.4.2 Analysis of the five forces model of China's new injection industry.
1) Analysis of existing competitors in the industry.
2) Potential entrant threats in the industry.
3) Industry Substitute Threat Analysis.
4) Analysis of the bargaining power of the industry.
5) Analysis of the bargaining power of industry buyers.
6) Summary of industry competition.
Chapter 3: Market Analysis of Different Ingredient Segments of Novel Injectables.
3.1 Market analysis of traditional Chinese medicine injections.
3.1.1 Introduction of traditional Chinese medicine injection products.
3.1.2 Classification of Chinese medicine injection products.
3.1.3 Market size of traditional Chinese medicine injections.
3.1.4 Competitive landscape of traditional Chinese medicine injections.
3.1.5 Main products of traditional Chinese medicine injections.
3.1.6 Development trend of traditional Chinese medicine injections.
3.1.7 Prospects for TCM injections**.
3.2 Chemical drug injection market analysis.
Chapter 4: Market Analysis of Novel Injectables by Technology Segment.
4.1 Nanoparticle Injection Market Analysis.
4.1.1 Introduction to nanoparticle injections.
4.1.2 Advantages of nanoparticle injection products.
4.1.3 Nanoparticle injection on the market.
4.1.4 Trends in nanoparticle injection technology.
4.1.5 Prospect analysis of nanoparticle injections.
4.2 Microsphere Injection Market Analysis.
4.2.1 Introduction to Microsphere Injection Products.
4.2.2 Advantages of microsphere injection products.
4.2.3 Launched products for microsphere injections.
4.2.4 Trends in microsphere injection technology.
4.2.5 Prospect analysis of microsphere injections.
4.3 Liposomal Injections Market Analysis.
City products. 4.4.4 Technology trends in microemulsion and submicroemulsion injections.
4.4.5 Prospect analysis of microemulsion and submicroemulsion injections.
4.5 PEGylated Drug Injection Market Analysis.
4.5.1 Introduction to PEGylated drug injection products.
4.5.2 Advantages of pegylated drug injection products.
4.5.3 PEGylated drug injection products on the market.
4.5.4 Trends in PEGylated drug injection technology.
4.5.5 Prospect analysis of pegylated drug injections.
4.6 Market analysis of gel administration injections.
4.6.1 Product introduction of gel administration injections.
4.6.2 Advantages of gel delivery injection products.
4.6.3 Gel-administered injections are marketed products.
4.6.4. Trends in gel-delivered injection technology.
4.6.5 Prospect analysis of gel-administered injections.
4.7 Inclusion Complex Injection Market Analysis.
4.7.1 Introduction to the product of inclusion complex injection.
4.7.2 Advantages of inclusion complex injection products.
4.8.4 Trends in long-acting injection technology.
4.8.5 Prospect analysis of long-acting injectables.
Chapter 5: Research and Prospect Analysis of Novel Injectable Technologies in China.
5.1 Research and prospect analysis of microneedle drug delivery technology.
5.1.1 Introduction and characteristics of microneedle drug delivery technology.
5.1.2 Research trends in microneedle drug delivery technology.
5.1.3 Launched products for microneedle drug delivery technology.
5.1.4 Prospects for the development of microneedle drug delivery technology.
5.2 Research and prospect analysis of needle-free injection technology.
5.2.1 Introduction and characteristics of needle-free injection technology.
5.2.2. Research trends in needle-free injection technology.
5.2.3 Needle-free injection technology on the market.
5.3.3 Liquid drug pre-filled injection technology marketed products.
5.3.4 Development prospect of liquid drug pre-filling injection technology.
Chapter 6: Analysis of Marketing Models and Strategies of the Novel Injection Industry.
6.1.2 Analysis of hospital terminal development.
1) Analysis of the development status of the hospital.
2) The size of the hospital drug market.
6.1.3 Analysis of the development of pharmacy terminals.
1) The growth of the number of pharmacies.
2) The size of the pharmacy terminal market.
6.1.4 Analysis of the development of the third terminal.
1) The development status of the third terminal.
2) The scale of drug use at the third end.
6.1.5 Drug terminal analysis.
1) The size of the drug terminal market.
2) Drug terminal market structure.
6.1.6 Problems in the industry's sales channels.
6.1.7. Industry sales channel management and strategy.
6.2 Analysis of the marketing model of the new injection industry.
6.2.1. Professional academic promotion and marketing model.
1) Characteristics of academic marketing model.
2) Classification of academic marketing models.
3) Advantages of academic marketing model.
4) Academic marketing team building.
6.2.2. Pharmaceutical marketing model.
1) The regional total system is completely total.
2) Regional distribution system.
3) Regional multi-class system.
6.2.3. Industry integrated marketing model.
1) Cost consolidation.
6.3.4 Danhong Injection: Academics Determine Acceleration.
6.3.5 Thrombosis for Injection: Specialized Three-dimensional Academic Promotion.
Chapter 7: Case Study of Key Novel Injectables Companies in China.
7.1. Overview of the development of enterprises in the new injection industry.
7.2 Case study of key domestic new injection enterprises.
7.2.1 Livzon Pharmaceutical Group Co., Ltd. ***
1) Brief analysis of enterprise development.
2) Analysis of business conditions.
3) Analysis of enterprise product structure.
4) Analysis of the company's new injection business.
5) Enterprise market channels and networks.
6) Analysis of the advantages and disadvantages of enterprise development.
2) Analysis of business conditions.
3) Analysis of enterprise product structure.
4) Analysis of the company's new injection business.
5) Enterprise market channels and networks.
6) Analysis of the advantages and disadvantages of enterprise development.
7) Analysis of the latest development trends of the enterprise.
7.2.4 Shandong Lukang Chenxin Pharmaceutical***
1) Brief analysis of enterprise development.
2) Analysis of business conditions.
3) Analysis of enterprise product structure.
4) Analysis of the company's new injection business.
5) Enterprise market channels and networks.
6) Analysis of the advantages and disadvantages of enterprise development.
7) Analysis of the latest development trends of the enterprise.
7.2.5 Harbin Yuheng Pharmaceutical Co., Ltd. ***
1) Brief analysis of enterprise development.
2) Analysis of business conditions.
3) Analysis of enterprise product structure.
4) Analysis of the company's new injection business.
5) Enterprise market channels and networks.
6) Analysis of the advantages and disadvantages of enterprise development.
7) Analysis of the latest development trends of the enterprise.
7.2.6 Chongqing Laimei Pharmaceutical Co., Ltd. ***
1) Brief analysis of enterprise development.
2) Analysis of business conditions.
3) Analysis of enterprise product structure.
4) Analysis of the company's new injection business.
5) Enterprise market channels and networks.
6) Analysis of the advantages and disadvantages of enterprise development.
7) Analysis of the latest development trends of the enterprise.
7.2.7 Shanghai Kaibao Pharmaceutical Co., Ltd. ***
1) Brief analysis of enterprise development.
2) Analysis of business conditions.
3) Analysis of enterprise product structure.
4) Analysis of the company's new injection business.
5) Enterprise market channels and networks.
6) Analysis of the advantages and disadvantages of enterprise development.
7) Analysis of the latest development trends of the enterprise.
7.2.8 Jiangsu Kangyuan Pharmaceutical Co., Ltd. ***
1) Brief analysis of enterprise development.
2) Analysis of business conditions.
3) Analysis of enterprise product structure.
4) Analysis of the company's new injection business.
5) Enterprise market channels and networks.
6) Analysis of the advantages and disadvantages of enterprise development.
7) Analysis of the latest development trends of the enterprise.
7.2.9 Guangxi Wuzhou Zhongheng Group shares***
1) Brief analysis of enterprise development.
2) Analysis of business conditions.
3) Analysis of enterprise product structure.
4) Analysis of the company's new injection business.
5) Enterprise market channels and networks.
6) Analysis of the advantages and disadvantages of enterprise development.
Chapter 8: Novel Injectables Industry Outlook** and Investment Recommendations.
8.1 Development trend and prospect of new injection industry**.
8.1.1. Analysis of industry development factors.
8.1.2 Industry Development Trends**.
1) Product trend analysis.
2) Technology trend analysis.
3) Competitive trend analysis.
4) Market trend analysis.
8.1.3 Industry development prospects**.
1) Overall demand for new injections**.
2) Segmentation of product demand for new injections**.
8.2 Investment status and risk analysis of the new injection industry.
8.2.1. Analysis of the current situation of industry investment.
8.2.2 Analysis of industry barriers to entry.
8.2.3. Analysis of industry business model.
8.2.4. Early warning of industry investment risks.
8.2.5. Industry mergers and acquisitions analysis.
8.3 Analysis of investment opportunities and hot spots in the new injection industry.
8.4.2 Strategic thinking on China's new injection enterprises.
8.4.3 Analysis of the development suggestions for China's new injection industry.
Table of Contents of Charts. Figure 1: Definition of novel injectables.
Figure 2: Breakdown of novel injectable products.
Figure 3: Characteristics of new injectable products.
Figure 4: Summary of industry standards for new injectables as of 2023.
Figure 5: Development plan of the new injection industry as of 2023.
Figure 6: China's GDP growth trend from 2017 to 2023 (unit: %)
Figure 7: Analysis of China's economic development trend from 2018 to 2023.
Figure 8: Summary of the current status of adverse reactions to injections in China as of 2023.
Figure 9: Analysis of the impact of the social environment on the new injectable industry.
Figure 10: Number and growth of Chinese population from 2017 to 2023 (unit: 10,000 people, %)
Figure 11: Proportion and change of China's population over 65 years old from 2017 to 2023 (unit: %)
Figure 12: Comparison of the degree of aging in China and the world's mainstream countries (unit: %)
Exhibit 26: Analysis of the economic characteristics of China's new injectable industry in 2023.
Figure 27: Statistics on the supply of new injections in China from 2017 to 2023 (unit: 10,000 tons, %)
Figure 28: China's new injection market size from 2017 to 2023 (unit: 100 million yuan, %)
Figure 29: Profitability of China's new injection industry from 2017 to 2023 (unit: 100 million yuan, %)
Figure 30: Gross profit margin of China's new injection industry from 2017 to 2023 (unit: %)
Chart 31: 2017-2023 China's new injection industry** trend (unit: yuan).
Exhibit 32: Competitive landscape of China's new injectable industry in 2023 (unit: %)
Exhibit 33: Current competition in China's new injectables industry.
Figure 34: Threat analysis of potential entrants in China's new injectable industry.
Figure 35: Threat analysis of alternatives in China's new injection industry.
Figure 36: Analysis of the bargaining power of China's new injection industry on upstream businessmen.
Figure 37: Analysis of the bargaining power of China's new injection industry to downstream customers.
Figure 38: Conclusion of the analysis of the five forces of China's new injection industry.
Exhibit 39: Introduction of Chinese medicine injection products and characteristics.
Exhibit 40: Classification of TCM injection products.
Figure 41: 2017-2023 Medication of traditional Chinese medicine injection in sample hospitals in nine key cities (unit: 100 million yuan, %)
Figure 42: Market size and growth of traditional Chinese medicine injection from 2017 to 2023 (unit: 100 million yuan, %)
Exhibit 43: Competitive landscape of TCM injections from 2017 to 2023 (unit: %)
Exhibit 44: Analysis of the current situation of major products of traditional Chinese medicine injections from 2017 to 2023.
Exhibit 45: Outlook for TCM injections from 2023 to 2031** (unit: 100 million yuan).
Exhibit 46: Introduction of chemical drug injection products and characteristics.
Exhibit 47: Chemical Injectable Product Classification.
Figure 48: Medication of traditional Chinese medicine injection in sample hospitals in nine key cities from 2017 to 2023 (unit: 100 million yuan, %)
Figure 49: Market size and growth of traditional Chinese medicine injection from 2017 to 2023 (unit: 100 million yuan, %)
Figure 60: Trends in microsphere injection technology.
Figure 61: Liposomal injection products and characteristics.
Figure 62: Liposomal Injectable Product Advantage Analysis.
Figure 63: Analysis of the current status of major marketed products for liposomal injections.
Figure 64: Trends in liposomal injection technology.
Exhibit 65: Microemulsion and submicroemulsion injection products and characteristics.
Figure 66: Analysis of the advantages of microemulsion and submicroemulsion injection products.
Figure 67: Analysis of the current status of major marketed products for microemulsion and submicroemulsion injections.
Figure 68: Technology development of microemulsion and submicroemulsion injections.
Exhibit 69: Pegylated drug injection products and their characteristics.
Exhibit 70: Analysis of the advantages of PEGylated drug injection products.
Exhibit 71: Analysis of the current status of major marketed products of pegylated drug injections.
Figure 72: Trends in PEGylated drug injection technology.
Exhibit 73: Gel-administered injectable products and their properties.
Exhibit 74: Analysis of the advantages of gel-delivered injectable products.
Figure 85: Introduction and characteristics of microneedle drug delivery technology.
Figure 86: Recent research trends in microneedle drug delivery technology.
Figure 87: Analysis of the current status of products on the market for microneedle drug delivery technology.
Exhibit 88: Prospect analysis of microneedle drug delivery technology.
Figure 89: Introduction and characteristics of needle-free injection technology.
Figure 90: Recent research trends in needle-free injection technology.
Figure 91: Analysis of the current status of products launched with needle-free injection technology.
Exhibit 92: Needle-free injection technology landscape analysis.
Exhibit 93: Introduction and characteristics of liquid drug prefill injection technology.
Exhibit 94: Recent research trends in liquid drug prefill injection technology.
Exhibit 95: Analysis of the current status of products on the market for liquid drug pre-filled injection technology.
Exhibit 96: Liquid drug prefill injection technology landscape analysis.
Figure 97: Analysis of the development status of hospitals in China from 2017 to 2023 (unit: households, 100 million yuan, %)
Exhibit 98: 2017-2023 hospital drug market size growth trend (unit: 100 million yuan, %)
Exhibit 109: Academic Marketing Expense Control Comparison.
Exhibit 110: Comparison of controls in academic marketing terminals.
Exhibit 111: Comparison of academic marketing product planning.
Exhibit 112: Comparison of academic marketing management levels.
Exhibit 113: Comparison of synergies in academic marketing strategies.
Figure 114: Comparison of marketing models of TCM injection companies.
Exhibit 115: Advantages and disadvantages of the regional complete aggregation system.
Exhibit 116: Advantages and disadvantages of the regional distribution system.
Exhibit 117: Advantages and disadvantages of the regional multi-tiered system.
Exhibit 118: Sales model of the new injection industry.
Exhibit 119: Comparison of various sales models in the new injection industry.
Figure 120: The core content of the marketing model of "Snow Lotus Injection".